SPARC‍‌‍‍‌‍‌‍‍‌ Share Price Jump Nearly 20% After Court-Favourable Ruling on Sezaby PRV

Tuesday, December 2, 2025: SPARC’s stock price went up by almost 20%, after a favourable positive court ruling in the US in favour of Sezaby PRV and its usage for the treatment of neonatal seizures. The share price reached the 20% upper circuit level record since July this year.

SPARC (Sun Pharma Advanced Research Co Ltd) was incorporated in 2006. The company is primarily involved in developing new drugs and novel drug delivery systems for global markets. The company has a substantial exposure in the US markets.

Meaning of the Verdict-PRV for Sezaby Granted.

The share price increase was due to the U.S. District Court for the District of Columbia’s summary judgment in SPARC’s favour on the issuance of a PRV for Sezaby (phenobarbital sodium injection). The court determined that the previous refusal of the PRV was “contrary to law” based on the cited statute, since no drug, or any type of phenobarbital sodium, had been “previously approved”- the court decision highlighted this aspect above all others.

This court ruling gives the FDA 60 days to file an appeal. It is also an environmentally friendly, benzyl alcohol- and propylene glycol-free product. The FDA has approved it as a safer seizure-inducing drug in infants.

Market Reaction & Trading Volumes Surge

With this news, SPARC shares saw very active trading, hitting the upper circuit at 19.99% at ₹161.02. However, even with the strong rally, the stock remains well below its 52-week high, with year-to-date performance still in negative territory. With no sellers available, the stock stayed at the upper circuit throughout the afternoon trading session.

After today’s surge, the 6-month return of the stock is around -19% and the YTD returns are close to -20%. The company’s P/E ratio is -16.31 compared to the industrial average of 33.48.

Importance of the PRV for Next

A PRV is a highly significant regulatory tool that promotes an accelerated approval process for a new drug and is most often considered as an asset that is tradable or licensable. That PRV granted for Sezaby suggests that SPARC can extend its growth potential over the long run. Besides this, the verdict can boost the company’s value, support investor trust, and facilitate capital raising or partnerships for the company. If a company were constantly investing in R&D and development; then such regulatory certainty would be a huge ‍‌‍‍‌‍‌‍‍‌plus.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations